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ABSTRACT
In obstructive lung diseases such as asthma and COPD dysp-
nea is a common respiratory symptom with different charac-
teristics given the different pathogenic mechanisms: in COPD
initially it can occur during exertion but then it increases pro-
gressively along with the airflow obstruction, whereas in
asthma it occurs episodically and is caused by transient bron-
choconstriction.
The language of dyspnea includes a large range of clinical
descriptors which have been evaluated for their correlation (of
one or several descriptors) with underlying physiologic/phys-
iopathologic mechanisms. These studies were done in asthma
rather than in COPD, and dyspnea descriptors were found to be
useful in identifying patients with life-threatening asthma.
However further studies are needed to further explore such
descriptors and their clinical utility.
This review discusses dyspnea mechanisms in various
obstructive lung disease subsets as well as the descriptors of
dyspnea and their utility in clinical practice.
Keywords: Descriptors, dyspnea, exercise testing, obstructive lung
diseases.
RIASSUNTO 
Nelle patologie ostruttive respiratorie come l’asma e la BPCO
la dispnea è un sintomo molto comune, con caratteristiche
differenti a seconda del meccanismo patogenetico sotteso:
nella BPCO si verifica inizialmente durante esercizio fisico per
poi incrementare progressivamente col progredire dell’ostru-
zione bronchiale, mentre nell’asma insorge episodicamente
ed è causata da un broncospasmo transitorio.
Il linguaggio della dispnea include un’ampia varietà di descrit-
tori clinici di cui è stata valutata la correlazione (di uno o più
descrittori) con i meccanismi fisiologici e fisiopatologici sot-
tostanti. Questi studi sono stati effettuati nell’asma piutto-
sto che nella BPCO ed i descrittori di dispnea sono stati ri-
scontrati utili per identificare i pazienti con asma in pericolo
di vita. Tuttavia studi ulteriori sono necessari per esplorare ul-
teriormente questi descrittori e la loro utilità clinica. In que-
sta rassegna vengono analizzati i meccanismi della dispnea
nei vari sottogruppi di patologie respiratorie di tipo ostrutti-
vo, come pure i descrittori di dispnea e la loro utilità nella pra-
tica clinica.
Parole chiave: Descrittori, dispnea, patologie ostruttive respi-
ratorie, test da sforzo. 
INTRODUCTION
Obstructive lung diseases are represented mainly by
asthma and by chronic obstructive pulmonary dis-
ease (COPD) which are both inflammatory diseases
of the airways but with different pathogenesis and
clinical manifestations: in asthma inflammation is
triggered and maintained usually by allergens, ren-
ders the bronchial muscle hyperreactive to various
stimuli including allergens themselves, and the con-
sequent bronchospasms manifest clinically with
episodic dyspnea and wheezing subsequently
relieved with rescue bronchodilator medication. In
COPD cigarette smoking exposure is the main risk
factor and the airways inflammation resulting from
such aggression is progressive, reducing the airways
lumen, and respiratory symptoms are dominated by
+ Sabina A. Antoniu 
University of Medicine and Pharmacy “Gr.T.Popa” Iasi, Department of Internal 
Medicine II- Pulmonary Disease, Pulmonary Disease University Hospital
30 Dr I Cihac Str, 700115 Iasi, Romania 
email: sabina.antonela.antoniu@pneum.umfiasi.ro  
Data di arrivo: 09/04/2010 – Accettato per la pubblicazione: 20/04/2010






escriptors of dyspnea – D
escrittori di disp
nea
dyspnea, cough and sputum production which
increase in severity with disease progression or dur-
ing disease exacerbations. 
Dyspnea is a common clinical denominator in both
asthma and COPD and its different characteristics
in the two diseases reflect the different pattern of
inflammation and of airways obstruction. This
review discusses separately the mechanisms of dys-
pnea in asthma and COPD, its descriptors, and their
clinical utility.
DYSPNEA IN COPD
In COPD dyspnea is one of the main respiratory
symptoms present during stable or exacerbated
state. It manifests initially during exertion and then,
as the disease progresses, also during rest. It is
caused by airflow obstruction which is secondary to
airways inflammation, airways remodelling and
sputum hypersecretion; reduced lung elastic recoil
due to emphysema and the obstruction of small air-
ways result in incomplete air expelling and dynam-
ic hyperinflation (“air trapping”) [1]. 
Mechanisms of dyspnea in COPD 
Overall exertional dyspnea in COPD is the result of
complex pathohysiological mechanisms including
dynamic hyperinflation, increased ventilatory
demand relative to impaired capacity, hypoxemia,
hypercapnia, and neuromechanical dissociation
(Table I) [1]. 
During exercise the reduced pulmonary elastic
recoil contributes to an increase in the end-expira-
tory lung volume, and dynamic hyperinflation (DH)
occurs. There are several adaptive mechanisms to
the DH, including the reconfiguration of the rib
cage in order to contain the overinflated lungs, and
an increased activity of the respiratory muscles, in
particular of the diaphragm, in order to generate
increased pressures able to compensate the
reduced elastic recoil, but such mechanisms can
usually be compensatory during resting or during
more reduced airways inflammation (such as in sta-
ble disease). During exertion or increased inflam-
mation (exacerbation) the increased DH impairs the
ability of the respiratory muscles to increase the
intrathoracic pressure in response to the increased
drive of breathing. The increased breathing rate is
consequent to the inability of the overinflated lung
to maintain or increase the inspiratory capacity dur-
ing exercise [2]. During exercise such abnormalities
are augmented by increased ventilatory demands
due to ventilation perfusion mismatches, metabolic
acidosis, hypoxemia, increased sympathetic tone,
etc. [1].
Gas exchange abnormalities occurring in COPD
patients during exercise are represented by arterial
hypoxemia and/or hypercapnia: the former occurs
in the milder COPD stages due to reduced ventila-
tion and shunting, whereas in more advanced
COPD alveolar hypoventilation adds to the above
mentioned mechanisms. Exercise hypercapnia in
COPD is due to reduced respiratory drive, breath-
ing patterns altered to minimize respiratory discom-
fort, or ventilatory muscle fatigue and has been
shown to be associated with greater dynamic hyper-
inflation [3]. 
Neuromechanical dissociation (NMD) between the
attempted and actual respiratory effort which
occurs between efferent motor neurons and afferent
fibers has been hypothesised as a physiopathogenic
mechanism in chronic obstructive pulmonary dis-
eases such as COPD and asthma [1]. In a study
evaluating the perception of exertional breathless-
ness during symptom-limited incremental cycle
exercise testing in normal subjects and in patients
with chronic airflow limitation, perceived inspirato-
ry difficulty was assessed with the Borg scale
(BorgIN), inspiratory effort was evaluated with
esophageal pressure expressed as a fraction of max-
imal esophageal pressure at isovolume
[Pes/PImax]), and breathing pattern, operational
lung volumes (end-expiratory/inspiratory lung vol-
umes [EELV/EILV]) were measured and compared at
a standard V˙O2 of 50% predicted maximum.
Breathlessness descriptors chosen and reported
immediately after exercise differed between normal
subjects and patients with chronic airflow obstruc-
tion. Descriptors of increased ‘work/effort’ and
‘heaviness’ of breathing were chosen by both nor-
mal subjects and patients with airflow obstruction
whereas the latter category constantly chose
descriptors such as ‘increased inspiratory difficulty’
(75%), ‘unsatisfied inspiratory effort’ (75%), and
‘shallow breathing’ (50%). The ratio of Pes/PImax to
VT/predicted VC was identified as the strongest cor-
relate with the Borg scale [4]. 
The differences between the quality of descriptors
for dyspnea among healthy subjects and patients
with airflow obstruction suggest that the latter cate-
gory receives altered peripheral sensory afferent
information from mechanoreceptors in the respira-
tory muscles, chest wall and lungs signaling to them
that the mechanical response of the ventilatory sys-
tem is insufficient or inappropriate for the effort
expended [5].
This sense of increased effort is believed to be the
result of corollary discharge relayed from the motor
cortex to the sensory cortex in the forebrain. Unlike
normal subjects, in whom respiratory effort matches
the ventilator demand both at rest and during exer-
cise, in patients with COPD there is increasing dis-
parity between effort and ventilatory output (i.e.
neuromechanical dissociation) which becomes
TABLE I: PATHOPHYSIOLOGICAL MECHANISMS OF DYSPNEA
IN COPD    
• Dynamic lung hyperinflation
• Increased ventilatory demand relative to impaired capacity 
• Hypoxemia
• Hypercapnia 






























9 more prominent as exercise progresses, because
dynamic hyperinflation constrains tidal volume
expansion. Consequently COPD patients experi-
ence intolerable dyspnea very quickly during exer-
cise, and describe it as ‘no room to breathe’ [5]. 
DYSPNEA IN ASTHMA
In asthma dyspnea is the clinical manifestation of
episodic bronchospasm, and its presence represents
a sign of suboptimal (therapeutic) control of the dis-
ease. Its severity can vary with the severity of the
asthma attack or exacerbation and it can be per-
ceived differently. For instance, some patients can
perceive promptly the mild respiratory symptoms
with increasing frequency, i.e. an asthma exacerba-
tion occurring while on maintenance therapy, and
can act promptly by self administering appropriate
medication in order to reduce the flared inflamma-
tion; other patients, on the contrary, are unable to
perceive appropriately such symptoms at their onset
and may seek medical care for a severe/life-threat-
ening asthma. 
Dyspnea perception in asthma can be influenced
by various factors (Table II) and knowledge of these
factors as well as of the descriptors of dyspnea may
contribute to improve disease control.
Dyspnea perception and its influencing factors in
asthma
In asthma it is difficult to differentiate between ‘nor-
mal’ and ‘abnormal’ (poor or exaggerated) percep-
tion of dyspnea [2]. Poor perception of dyspnea
means underestimation of its severity and this has
been demonstrated to be a major risk factor for life-
threatening asthma (LTA) and disease
morbidity/mortality: in a study evaluating symptoms
perception in subjects undergoing methacoline
bronchoprovocation testing, about 15% of the 82
patients with a fall of FEV1 to values < 50% predict-
ed were reported to be asymptomatic, whereas in
another study in patients with history of near fatal
asthma perception of dyspnea during external resis-
tive loading was found to be lower compared to
normal subjects but comparable to that of patients
with non fatal asthma, and low perception of dysp-
nea was found to be associated with significantly
longer hospitalisations, near fatal exacerbations
and/or death [6-8]. 
In asthma, dyspnea is usually described as ‘chest
tightness’, increased ‘effort’ or ‘work’ of breathing,
or ‘difficult breathing’, and it has been demonstrat-
ed that the symptom quality varies with the degree
of bronchoconstriction, e.g. the tightness was found
to be associated with mild bronchoconstriction and
attributed to vagal stimulation due to increased air-
ways resistance but not to dynamic hyperinflation
[9].
However, in a study evaluating the relationship
between respiratory symptom intensity and quality
and dynamic lung hyperinflation during bron-
choconstriction induced by high-dose metha-
choline challenge (maximum decrease in FEV1 of
50% from baseline in asthma) in which the qualita-
tive descriptors of dyspnea and functional residual
capacity (FRC) were measured at the doses nearest
to the provocative concentration of methacholine
causing a 20% fall in FEV1(PC20) and at the highest
dose of methacholine (maximum response), asthma
patients selected descriptors such as ‘inspiratory dif-
ficulty’, ‘chest tightness’, ‘unsatisfied inspiration’, or
‘work’ at the dose nearest to PC20 but were more
frequently selected at the highest methacholine
dose. Furthermore patients who reported chest
tightness at maximum response had greater airflow
obstruction and dynamic hyperinflation than those
who did not report chest tightness [10]. 
Under therapy, the frequency of reporting descrip-
tors such as ‘chest tightness’ has been found to
decrease, whereas the frequency of reporting others
such as ‘work’ or ‘breathing effort’ persisted con-
comitantly with airflow obstruction [11,12].
CONCLUSIONS
The clinical descriptors of dyspnea in asthma and
COPD can be relevant for both diagnostic and ther-
apeutic purposes: in the initial clinical evaluation of
an unexplained dyspnea they might be able to pro-
vide information which is additional to the evalua-
tion of physiologic parameters, e.g. in a patient with
COPD asymptomatic at rest, obtaining descriptors
for exertional dyspnea factors can help in identify-
ing the limiting factor of the exercise capacity, or in
a patient with asthma certain dyspnea descriptors
can signal suboptimal therapeutic control of disease
or may help in detecting life threatening forms of
asthma. 
The language of dyspnea includes a large range of
descriptors, and although a certain amount of
research evaluating the correlation of one or several
descriptors with underlying physiologic/pathophys-
iologic mechanisms has been already done, more
studies are needed to further explore such descrip-
tors and their clinical utility. 
Such studies can be greatly helped by the use of
dyspnea questionnaires which offer standardized
clinical descriptors able to detect rapidly the cause
of breathing abnormalities: despite the fact such
questionnaires are commonly used in COPD to
evaluate dyspnea and the effects of various thera-
TABLE II: FACTORS AFFECTING SYMPTOMS PERCEPTION IN
ASTHMA    
• Advanced age 
• Suboptimal disease therapeutic control (presence of airways 
hyperreactivity, peak expiratory flow variability)
• Chronic airflow obstruction
• Asthma medications
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pies on its severity, few studies have focused on dys-
pnea descriptors and their clinical utility in COPD;
this has more frequently been done in asthma and
the results obtained and discussed above should
encourage similar studies in COPD.
Overall documentation of dyspnea descriptors in
obstructive lung diseases has, beyond pure research
interest, a clinical applicability in disease diagnosis,
in severity ascertainment and in therapeutic follow
up, and further studies can therefore improve the
knowledge in the field.
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